537 results on '"Von Laer, Dorothee"'
Search Results
2. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
3. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
4. Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system
5. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
6. Therapeutic Efficacy of a VSV-GP-based Human Papilloma Virus Vaccine in a Murine Cancer Model
7. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
8. TOP-359-YI Development of a replication-competent Vesicular Stomatitis Virus (VSV) vector for therapeutic hepatitis B vaccination
9. Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population
10. Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
11. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
12. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
13. Disproportionate preponderance of HPV genotypes associated with anogenital warts among HIV-positive MSM.
14. Machine Learning to Identify Critical Biomarker Profiles in New SARS-CoV-2 Variants
15. Detection of infectious SARS-CoV-2 in ocular samples is linked to viral load in the nasopharynx
16. Terminal Ileitis as the Exclusive Manifestation of COVID-19 in Children.
17. Highly Specific Sars-Cov-2 Main Protease (Mpro) Mutations Against the Clinical Antiviral Ensitrelvir Selected in a Safe, Vsv-Based System
18. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
19. Durability of cross-neutralizing antibodies 5.5 months after bivalent COVID-19 booster
20. Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein
21. High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl
22. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
23. Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community
24. Anal Ureaplasma spp. positivity among HIV positive men who have sex with men may be associated with high-risk-type HPV infections
25. A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system
26. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
27. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
28. Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination
29. Viral infection in chronic otitis media with effusion in children
30. C Peptides as Entry Inhibitors for Gene Therapy
31. Data from Decreased Tumor Surveillance after Adoptive T-Cell Therapy
32. Data from Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency
33. Supplementary Figures 1 - 7 from Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency
34. Supplementary Figure 2 from Decreased Tumor Surveillance after Adoptive T-Cell Therapy
35. Supplementary Legends 1-2 from Decreased Tumor Surveillance after Adoptive T-Cell Therapy
36. Supplementary Figure 1 from Decreased Tumor Surveillance after Adoptive T-Cell Therapy
37. SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
38. Reduced sensitivity of antibody tests after omicron infection
39. High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz
40. Can high COVID-19 vaccination rates in adults help protect unvaccinated children? Evidence from a unique mass vaccination campaign, Schwaz/Austria, March 2021
41. Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
42. Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot
43. Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria
44. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout
45. SARS-CoV-2 3CLpro mutations confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system
46. Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
47. N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro
48. BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants
49. Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
50. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.